-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The epidemiological and clinical significance of cardiomyopathy in Neo crown pneumonia (COVID-19) is still not fully clear.
study aims to determine the rate and prognosis of cardiomyopathy in patients with severe COVID-19 compared to acute respiratory distress syndrome (ARDS) in non-COVID-19.
to assess tcalledtenin levels in patients treated with COVID-19 in five hospitals from March 15 to June 11, 2020.
researchers compared them with patients from the ARDS Myocardial Injury Queue study and performed a survival analysis of the main outcomes of hospital deaths associated with cardiomyopathy.
addition, I used linear regression to determine the clinical factors associated with COVID-19 cardiomyopathy.
A total of 243 COVID-19 patients were included in the prognosis of patients with tyrocalin levels, of which 51% had higher than normal titrogen levels, and chronic kidney disease, lactic acid, ferrin and fibrinogen were all associated with cardiomyopathy.
of COVID-19 patients with tspolin below the upper limit of the normal value had a mortality rate of 22.7%, while the mortality rate of patients with tsporine levels 10 times higher than the upper limit of the normal value was as high as 61.5%.
the correlation between heart muscle injury and mortality was not statistically significant after the adjustment of age, sex and multi-system organ dysfunction.
the survival curve of COVID-19 patients was older, higher creatinine level and poor vital signs compared with ARDS patients who were not COVID-19.
, the risk of cCOVID-19-related ARDS cardiomyopathy injury was lower than that of non-COVID-19-related ARDS (advantage ratio of 0.55 (95% CI, 0.36-0.84); P=0.005)。
, similar to traditional ARDS, the risk of cardiomyopathy in patients with SEVERE COVID-19 is associated with baseline co-disease, advanced age, and multi-system organ dysfunction.
adverse prognosmation of COVID-19 cardiomyopathy is mainly related to multi-system organ injury and critical disease.
